期刊文献+

评估纸片扩散法与 Vitek2-compact GN13测定肠杆菌科细菌体外药敏及 ESBLs 可靠性的研究 被引量:11

Evaluation of the capabilities of disc diffusion and Vitek2-compact GN13 methods for testing antimi-crobial susceptibility and screening of ESBLs Enterobacteriaceae clinical isolates
原文传递
导出
摘要 目的:评估纸片扩散法与Vitek2-compact GN13测定肠杆菌科细菌体外药敏及ESBLs的可靠性。方法本研究选取了2011—2012年从21家医院腹腔感染患者中分离的93株肠杆菌科细菌。分别采用纸片扩散法、Vitek2-compact GN13、微量肉汤稀释法测定其对氨苄西林-舒巴坦、哌拉西林-他唑巴坦、厄他培南、头孢他啶、头孢曲松、头孢吡肟、亚胺培南、阿米卡星、环丙沙星和左氧氟沙星的体外敏感性。以微量肉汤稀释法作为参考方法,分别评估纸片扩散法、Vitek2-compact GN13与参考方法的分类一致率( CA%)。利用PCR及测序法,在大肠埃希菌、肺炎克雷伯菌、产酸克雷伯菌和奇异变形杆菌中筛选超广谱β-内酰胺酶( ESBLs)耐药基因,评估纸片扩散法与Vitek2-compact GN13表型确证试验筛选ESBLs的敏感性、特异性、阳性预测值和阴性预测值。结果纸片扩散法和Vitek2-compact GN13与参考方法的一致率均>90%;但在使用Vitek2-compact GN13测定厄他培南、氨苄西林-舒巴坦、头孢他啶和头孢吡肟时,会出现一定比例的大错误( ME,3.2%)和极大错误( VME,2.2%)。此外,纸片扩散法和Vitek2-compact GN13对产ESBLs菌株测定的敏感性、特异性、阳性预测值、阴性预测值分别为96.7%(29/30)、100%(20/20)、100%(30/30)和95%(19/20)。结论无论是纸片扩散法还是Vitek2-compact GN13,对肠杆菌科细菌体外药敏及ESBLs的测定均比较可靠。但在采用Vitek2-compact GN13测定厄他培南、氨苄西林-舒巴坦、头孢他啶和头孢吡肟时,应注意可能出现ME及VME。 Objective To evaluate the capabilities of disc diffusion and Vitek2-compact GN13 methods for testing antimicrobial susceptibility of screening ESBLs ( extended-spectrumβ-lactamase) in En-terobacteriaceae clinical isolates.Methods A total of 93 Enterobacteriaceae strains were isolated from pa-tients with intra-abdominal infections in 21 hospitals during 2011 to 2012.The in vitro minimum inhibition concentration ( MIC ) values of ampicillin-sulbactam, piperacillin-tazobactam, ertapenem, ceftazidime, ceftriaxone, cefepime, imipenem, amikacin, ciprofloxacin and levofloxacin were determined by disc diffu-sion, Vitek2-compact GN13 and broth microdilution methods, respectively.Categorical agreement ( CA ) rates of disc diffusion and Vitek2-compact GN13 methods were determined by using broth microdilution meth-od as the reference method.The genes encoding ESBLs were screened in Escherichia coli (E.coli), Kleb-siella pneumoniae (K.pneumonia), Klebsiella oxytoca (K.oxytoca) and Proteus mirabilis (P.mirabilis) strains by using PCR analysis and gene sequencing.Disc diffusion and Vitek2-compact GN13 methods were used for the phenotypic confirmatory test of ESBLs and the sensitivity, specificity, positive predictive value and negative predictive value of the two tests were evaluated.Results The CA values of disc diffusion and Vitek2-compact GN13 methods for the 10 antibiotics were all 〉90% as compared with broth microdilution method.The major error (ME) rate for ertapenem was 3.2%and the very major error (VME) rates for am- picillin-sulbactam, ceftazidime and cefepime tests were all 2.2% by using Vitek2-compact GN13 method. The sensitivity, specificity, positive predictive value and negative predictive value of disc diffusion and Vitek2-compact GN13 methods in the phenotypic confirmatory test of ESBLs were 96.7%(29/30), 100%(20/20), 100%(30/30) and 95%(19/20), respectively.Conclusion Both disc diffusion and Vitek2-compact GN13 methods could be used for testing the antimicrobial susceptibility and the detection of ESBLs in Enterobacteriaceae clinical isolates with the advantage of accuarcy.Attention should be paid to the posibil-lity of oaurance of ME and VME when testing ertapenem, ampicillin-sulbactam, ceftazidime and cefepime by using Vitek2-compact GN13 method.
出处 《中华微生物学和免疫学杂志》 CAS CSCD 北大核心 2015年第2期139-145,共7页 Chinese Journal of Microbiology and Immunology
关键词 纸片扩散法 VITEK2 微量肉汤稀释法 一致率 超广谱β-内酰胺酶 Disc diffusion method Vitek2 Broth microdilution method Categorical agreement Extended spectrumβ-lactamase
  • 相关文献

参考文献18

  • 1Clinical and Laboratory Standard Institute. M100-S23 Performance standards for antimicrobial susceptibility testing; twenty-third in- formational supplement[ S]. CLSI document M100-S23. Wayne, PA: CLSI, 2013.
  • 2Clinical and Laboratory Standard Institute. M02-A11 Performance standards for antimicrobial disk susceptibility tests; approved standard-eleventh edition [ S ]. CLSI document. Wayne, PA : CLSI, 2012.
  • 3Clinical and Laboratory Standard Institute. M07-A9 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aer- obically; approved standard-ninth edition [ S ]. Wayne, PA: CI2SI, 2012.
  • 4Tatman-Otkun M, GUrcan S, Ozer B, et al. The antimierobial susceptibility of Stenotrophomonas maltophilia isolates using three different methods and their genetic relatedness [ J ]. BMC Microbi- ol, 2005, 5: 24.
  • 5Kuper KM, Boles DM, Mohr JF, et al. Antimierobial susceptibili- ty testing: a primer for clinicians [ J ]. Pharmaeotherapy, 2009, 29( 11 ) : 1326-1343.
  • 6Jorgensen JH. Selection criteria for an antimicrobial susceptibility testing, svstem[J]. J Clin Mierobiol. 1993.31 ( 11 ) : 2841-2844.
  • 7杨启文,徐英春,王辉,谢秀丽,陈民钧.CTX-M酶在北京协和医院临床分离大肠埃希菌中的流行[J].中国感染与化疗杂志,2006,6(1):1-6. 被引量:23
  • 8黎晓强,卓超,肖书念,钟南山.广州地区产CTX—M-15的大肠埃希菌的系统发育群的研究[J].中华检验医学杂志,2010,33(2):152-154. 被引量:4
  • 9王辉,刘颖梅,王清涛,孙宏莉,陈民钧.北京发现同时产DHA-1质粒AmpC型及CTX-M型超广谱β-内酰胺酶的肺炎克雷伯菌[J].中华微生物学和免疫学杂志,2005,25(5):419-422. 被引量:38
  • 10Clinical and Laboratory Standard Institute. M100-S22 Performance standards for antimicrobial susceptibility testing; 22nd information- al supplement[S]. Wayne, PA: CLSI, 2012.

二级参考文献29

  • 1肖庆忠,苏丹虹,江洁华,钟南山.广州地区革兰阴性杆菌CTX-M和OXA型广谱β-内酰胺酶基因分型研究[J].中华医院感染学杂志,2005,15(12):1321-1326. 被引量:34
  • 2Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrobial Chemother, 2007, 59 : 165-174.
  • 3Herzer PJ, Inouye S, Inouye M, et al. Phylogenetic distribution of branched RNA-linked multicopy single-stranded DNA among natural isolates of Escherichia coli. J Bacteriol, 1990, 172: 6175- 6181.
  • 4Coque TM, Novais A, Carattoli A, et al. Dissemination of clonally related Escherichia coli strains expressing extended-spectrum beta- Lactamase CTX-M-15. Emerg Infect Dis,2008, 14: 195-200.
  • 5Boyd EF, Hartl DL. Chromosomal regions specific to pathogenic isolates of Escherichia coli have a phylogenetically clustered distribution. J Bacterial, 1998, 180 : 1159-1165.
  • 6Clermont O, Bonacorsi S, Bingen E. Rapid and simple determination of the Escherichia coli phylogenetic group. Appl Environ Microbiol, 2000, 66 : 4555-4558.
  • 7Martinez JA, Soto S, Fabrega A, et al. Relationship of phylogenetic background, biofilm production, and time to detection of growth in blood culture vials with clinical variables and prognosis associated with Escherichia coli bacteremia. J Clin Microbiol, 2006, 4 : 1468-1474.
  • 8Sanders CC, Peyret M, Moland ES, et al. Ability to the VITEK-2 advanced expert system to indentify beta-lactam phenotypes in isolates of enterobac-teriaceae and pseudomonas aeruginosa [J]. J Clin Microbiol, 2000, 38 (2) :570-574.
  • 9National Committee for Clinical Laboratory Standards. Performanee standard for antimicrobial testing lnineteenth informational supplement[J]. NCCLS, 2009,24 (1) : 120-125.
  • 10Joyanes P, Carmen M, Martinez L, et al. Evaluation of the VITEK2 system for the identification and susceptibility of three species of nonfermenting gram-negative rods frequently isolated from clinical samples[J]. J Clin Microbiol, 2001,39 (9) : 3247-3253.

共引文献62

同被引文献53

引证文献11

二级引证文献27

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部